TITLE:
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

CONDITION:
Schizophrenia

INTERVENTION:
Lurasidone

SUMMARY:

      A 6-week in-patient and out-patient study to test the effectiveness and safety of a new
      medication in the treatment of schizophrenia
    

DETAILED DESCRIPTION:

      Study will evaluate the efficacy of a new compound versus placebo in the treatment of
      patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from
      baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from
      the Positive and Negative Syndrome Scale (PANSS).
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 64 Years
Criteria:

        Inclusion Criteria:

          -  Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV

          -  The patient must agree to a voluntary hospitalization duration of 31 days minimum at
             the start of the treatment

          -  If female, must not be pregnant, or must be incapable of conceiving or be taking
             steps to prevent conception

        Exclusion Criteria:

          -  The patient has used an investigational drug within the past 30 days

          -  The patient has participated in a previous study of this compound
      
